(Q38205702)

31 August 2017

Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment (English)

1 reference

31 August 2017

1 reference

3

Steven E Lipshultz

1 reference

31 August 2017

Shashi Raj

1

1 reference

PubMed ID

24748018

31 August 2017

Vivian I Franco

series ordinal

2

1 reference

PubMed ID

24748018

31 August 2017

language of work or name

1 reference

1 June 2014

1 reference

Current treatment options in cardiovascular medicine

31 August 2017

1 reference

31 August 2017

16

1 reference

31 August 2017

6

1 reference

31 August 2017

315

1 reference

https://scigraph.springernature.com/pub.10.1007/s11936-014-0315-4

31 August 2017

0 references

cites work

Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Anthracycline associated cardiotoxicity in survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Anthracycline-induced cardiotoxicity in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Characteristics and determinants of adiposity in pediatric cancer survivors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cardiac or cardiopulmonary transplantation in childhood cancer survivors: an increasing need?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Doxorubicin-induced apoptosis in caspase-8-deficient neuroblastoma cells is mediated through direct action on mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Doxorubicin-induced apoptosis: implications in cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Carvedilol in children with cardiomyopathy: 3-year experience at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Molecular and cellular mechanisms of anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Modifiable risk factors and major cardiac events among adult survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cardiac changes associated with growth hormone therapy among children treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Biomarkers in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11936-014-0315-4

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

21 January 2018

1 reference

12 December 2020

Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex

1 reference

12 December 2020

Cardiotoxicity after childhood cancer: beginning with the end in mind

1 reference

12 December 2020

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

1 reference

12 December 2020

Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis

1 reference

12 December 2020

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

1 reference

12 December 2020

Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration 1Supported in part by NIH Grant HL58016. The manuscript was not subjected to internal Agency review and, thus, the opinions are those of the

1 reference

12 December 2020

Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer

1 reference

12 December 2020

Endocrine sequelae in survivors of childhood cancer

1 reference

12 December 2020

Cardiac Magnetic Resonance Imaging in the Evaluation of the Late Effects of Anthracyclines Among Long-Term Survivors of Childhood Cancer

1 reference

12 December 2020

Clinical pharmacology of dexrazoxane.

1 reference

12 December 2020

Cardiomyopathy Caused by Antineoplastic Therapies

1 reference

12 December 2020

Long-term cause-specific mortality among survivors of childhood cancer

1 reference

12 December 2020

Exercise capacity in long-term survivors of pediatric cancer: an analysis from the Cardiac Risk Factors in Childhood Cancer Survivors Study

1 reference

12 December 2020

High risk of symptomatic cardiac events in childhood cancer survivors

1 reference

12 December 2020

Epidemiology of anthracycline cardiotoxicity in children and adults.

1 reference

12 December 2020

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

12 December 2020

Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease

1 reference

12 December 2020

Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study

1 reference

12 December 2020

10.1007/S11936-014-0315-4

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24748018